Last reviewed · How we verify
Silymarin capsule simulant
Silymarin is a flavonolignan mixture that protects hepatocytes through antioxidant and anti-inflammatory mechanisms, stabilizing cell membranes and promoting liver regeneration.
Silymarin is a flavonolignan mixture that protects hepatocytes through antioxidant and anti-inflammatory mechanisms, stabilizing cell membranes and promoting liver regeneration. Used for Liver protection and support in hepatic disorders, Adjunctive therapy for chronic liver disease, Drug-induced liver injury prevention.
At a glance
| Generic name | Silymarin capsule simulant |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Herbal extract / Hepatoprotective agent |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Silymarin, derived from milk thistle seeds, acts as a potent antioxidant that scavenges free radicals and inhibits lipid peroxidation in liver tissue. It stabilizes hepatocyte membranes, reduces inflammatory cytokine production, and enhances protein synthesis to support liver cell recovery and regeneration. The compound also modulates phase I and II detoxification enzymes, improving the liver's capacity to metabolize xenobiotics and toxins.
Approved indications
- Liver protection and support in hepatic disorders
- Adjunctive therapy for chronic liver disease
- Drug-induced liver injury prevention
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
- Headache
Key clinical trials
- The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: